Natera and TransCode to Collaborate on Phase 2a Cancer Trial
Natera and TransCode Therapeutics announced a collaboration on a Phase 2a trial of TTX-MC138 in colorectal cancer.
Story updates
11:30:46 AM UTC
SquawkNews
Natera will use its Signatera MRD test to identify colorectal cancer patients for TransCode’s Phase 2a TTX-MC138 trial in the PRE-I-SPY program.Material DetailsContext by AI AnalystThis is an early-stage strategic move to tie Signatera to an interventional CRC trial, extending MRD use beyond detect…